Lipo-ImmunoTech was founded on the goal of advancing anti-cancer strategies and/or neurodegenerative diseases that have strong mechanistic data and can dramatically benefit patient health. Our company offers innovation in anti-cancer strategies utilizing lipid metabolism/signaling and immuno-therapy. Both pathways for treatment provides a two-prong approach for attacking cancer through novel chemotherapeutics by targeting lipid metabolism/signaling and by strengthening the natural anti-cancer activity of the immune system, which provide unique set of expertise and leadership.
Research Infrastructure
Lipo-ImmunoTech is a spin-off company from the Medical University of South Carolina. Founders Drs. Ogretmen and Mehrotra are field-leading scientists, who maintain NIH-funded laboratories and active publications in top journals. Our research space is located at the Hollings Cancer Center and directly overseen by Drs. Ogretmen and Mehrotra. Our medical director, Dr. Lilly, is a physician scientist, who is one of the leading oncologists at the Hollings Cancer Center with national and international reputation.